top of page
Studying Tumor Evolution & Therapy Response
Lab News
We are now part of SFB1310
Based on our joined publication with Johannes Berg at the Institute of Theoretical physics (link) we have designed a follow-up project that uses evolutionary modelling to prevent drug resistance in EGFR-mutant Lung Cancer. Very happy that we will be able to pursue this as a part of the SFB130 Predictability in Evolution!
Welcome, Marek!
Marek started in the lab! As our new postdoctoral fellow Marek will work on methods to dissect tumor heterogeneity and clonal evolution under therapy using single cell sequencing of cell line models and cancer samples.
Welcome, Zoe!
Zoe just joined our lab as an MD student aiming to understand the mechanisms by which anti-apoptotic proteins modulate drug response in Non-Small Cell Lung Cancer.
Investigation of therapy resistance in EGFR-driven lung cancer by additional mutations in BRAF published
Targeted therapy is first-line therapy for lung tumors with EGFR mutations. However, the success of the therapy is limited. In our recent project published in npj Precision Oncology, we therefore took a translational approach to study the clonal evolution of EGFR mutant lung cancer that developed therapy resistance due to additional mutations in the BRAF gene. Coupled with in vitro functional genomics we thereby clarify resistance mutations we hope to contribute to improved treatment of EGFR-mutant lung cancer patients. (Link to publication)
Our study combining kinase inhibition with agonists of innate immune sensor RIG-I published to treat cancer is out in Nature Communications
In this study we investigated cancer cells that survive treatment with targeted kinase inhibitors and observed that they frequently upregulate an inflammatory response that impacts tumor and immune cells. We further found that this can be exploited using a nucleic acid receptor agonist stimulating RIG-I to treat kinase-driven cancers in vitro and in vivo. Results out now in Nature Communications. (Link to publication)
We are now officially part of the CRC1399
The Brägelmann Lab is now officially part of the CRC1399 (SFB1399). Very happy and honored to study the mechanisms of drug sensitivity and resistance in Small Cell Lung Cancer (SCLC) with such an excellent group of leading SCLC researchers. (Link to CRC homepage)
Two new lab members have joined the team
A very warm welcome to Alessia and Philipp, two highly motivated and enthusiastic MD students that have joined our team. Looking forward to investigate the molecular mechanisms of cell death, therapy response and innate immune processes in cancer cells with you!
Brägelmann Lab now affiliated with the Center for Molecular Medicine Cologne (CMMC)
Our group has been awarded status as an associated research group at the Center for Molecular Medicine (CMMC) at the University Hospital Cologne as part of their Career Advancement Program. (CMMC homepage)
bottom of page